Heart Test Laboratories (Heart Test Laboratories) EBITDA Margin % : -10,146.67% (As of Jan. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Heart Test Laboratories EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Heart Test Laboratories's EBITDA for the three months ended in Jan. 2024 was $-1.52 Mil. Heart Test Laboratories's Revenue for the three months ended in Jan. 2024 was $0.02 Mil. Therefore, Heart Test Laboratories's EBITDA margin for the quarter that ended in Jan. 2024 was -10,146.67%.

Heart Test Laboratories EBITDA Margin % Historical Data

The historical data trend for Heart Test Laboratories's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heart Test Laboratories EBITDA Margin % Chart

Heart Test Laboratories Annual Data

Trend

Apr20

Apr21

Apr22

Apr23

EBITDA Margin %

-5,850.00

-8,792.31

-31,642.86

-121,680.00

Heart Test Laboratories Quarterly Data
	Apr20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EBITDA Margin %	Get a 7-Day Free Trial									-65,100.00	-	-	-39,050.00	-10,146.67

Competitive Comparison of Heart Test Laboratories's EBITDA Margin %

For the Medical Devices subindustry, Heart Test Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heart Test Laboratories's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Heart Test Laboratories's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Heart Test Laboratories's EBITDA Margin % falls into.

Heart Test Laboratories EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Heart Test Laboratories's EBITDA Margin % for the fiscal year that ended in Apr. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Apr. 2023 )	/	Revenue (A: Apr. 2023 )
	=	-6.084	/	0.005
	=	-121,680.00 %

Heart Test Laboratories's EBITDA Margin % for the quarter that ended in Jan. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jan. 2024 )	/	Revenue (Q: Jan. 2024 )
	=	-1.522	/	0.015
	=	-10,146.67 %

Heart Test Laboratories (NAS:HSCS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Heart Test Laboratories EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Heart Test Laboratories's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Heart Test Laboratories (Heart Test Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heart Test Laboratories Inc (NAS:HSCS) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

550 Reserve Street, Suite 360, Southlake, TX, USA, 76092

Website

https://www.heartsciences.com

Heart Test Laboratories Inc is a medical technology company focused on applying innovative AI-based technology to an ECG to expand and improve an ECG's clinical usefulness. The objective of the company is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings.

Executives

David R. Wells	director	2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Bruce Bent	director	750 BONHAM PARKWAY, LANTANA TX 76226
Mark T Hilz	director, officer: See Remarks	3301 DAKOTA DRIVE, NORTHLAKE TX 76226
Patrick Kanouff	director	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Brian Szymczak	director	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Danielle Watson	officer: See Remarks	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Andrew Simpson	director, officer: See Remarks	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092